Skip to content

Novavax NVAX Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies

Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$340.63M-22.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$101.48M+46.4%
Moderna logo
ModernaMRNA
Roivant Sciences logo
Roivant SciencesROIV
Gilead Sciences logo
Gilead SciencesGILD
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+35.6%
Enterprise value$1.53B+76.9%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Novavax (NVAX) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $147.29M in Q1 2026.
How has Novavax's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
Novavax's proceeds from maturities, prepayments and calls of debt securities, available-for-sale increased by 242.5% year-over-year, from $43M to $147.29M.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.